This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of
E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD)
chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the treatment of
relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are at a higher risk for
failure of CAR-T therapy.